-
-
While the Jarvik 7 is generally considered to be the first artificial heart, it was not the first design for such a device.
-
Israel has provided fertile soil for developing a broad range of medical technologies. The reasons are probably several-fold but two of them stand out: Israel is an inherently entrepreneurial culture, given the everyday risk-taking required to live there; and the country has a disproportionately high percentage of physicians, often with innovative ideas that can be turned into commercializable products.
-
Stem cells where to get them and how to grow them into the right cell type have gotten much of the attention in the quest for making organs for transplantation. But getting any sort of tissue is not in itself enough: to grow an organ, the right cell types need to grow into the proper shape.
-
Device and pharmaceutical company Angiotech Pharmaceuticals (Vancouver, British Columbia) has made good on what it promised early last year: to file for FDA clearance of its anti-infective 5-Fluorouracil-coated (5-FU) Central Venous Catheter (CVC) before year's end.
-
SAN FRANCISCO Strung with white-and-turquoise canvas bags as they made their ways through the packed hallways of the Westin St. Francis hotel here, attendees took in the final full events of the 26th annual JPMorgan Healthcare Conference in early January.
-
Affymetrix (Santa Clara, California) reported that the University of Ottawa Heart Institute (UOHI; Ottawa, Ontario) is using the Affymetrix Genome-Wide Human SNP (single nucleotide polymorphisms) Array 6.0 for its whole-genome association study on coronary artery disease (CAD).
-
Abiomed (Danvers, Massachusetts) rang in year 2008 by issuing an update to its European strategy to drive growth by establishing the concept of recovery as the goal for patients experiencing acute cardiac events.
-
Boston Scientific (Natick, Massachusetts) reported that it has signed an agreement to sell its fluid management and venous access businesses for $425 million in cash to private equity firm Avista Capital Partners, thereby, it said last month, completing its program for spinning off what it termed "non-stategic" assets.
-
Bristol-Myers Squibb (BMS; New York) reported in mid-December that it would sell its Medical Imaging (BMS-MI) unit in Billerica, Massachusetts, to private equity firm Avista Partners (New York) for $525 million in cash.
